🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Next generation bioconjugates against influenza virus infection: The Hackenberger group The Hackenberger Group FMP Berlin and Herrmann group Freie Universität report double functionalized virus particles for trivalent virus binding and demonstrate cell interaction go.acs.org/1KT

Meet our CEO Dominik Schumacher & CSO Jonas Helma-Smets at the World ADC congress in San Diego, where they will give two presentations on Tubulis’ differentiated #ADC platform approaches. To connect with us on site, reach out via [email protected].

Check out the latest issue of European Pharmaceutical Review, where our CEO Dominik Schumacher & CSO Jonas Helma-Smets discuss advancements in #ADC development & how Tubulis’ unique conjugation platform approach aims to address current shortcomings in the field: bit.ly/3PYffXp

Interested in the future of #ADCs? Talk to our team at the upcoming World ADC congress in San Diego about our partnering & collaboration opportunities. Reach out to us via [email protected] for a chat on-site.

Don’t miss our CEO Dominik Schumacher giving a talk at the World ADC congress in San Diego tomorrow about our unique conjugation technologies to enable safe payload delivery & make the right match when it comes to #ADC design.

Check out our joint publication with @LMU_Uniklinikum, DKTK & FMP Berlin in @BloodJournal on 20D9-ADC, an #ADC created with our P5 conjugation technology targeting FTL3 in #AML, showing significant & durable tumor reduction in mouse models. Click here: bit.ly/3QNtsHG

Don’t miss our CMO, Günter Fingerle-Rowson EORTC’s CLTG meeting where he will present new data on our #lymphoma-targeting #ADC candidate TUB-010, based on our Tub-tag conjugation technology. For more information: bit.ly/3Baq0BP

#DYK there are 500.000 newly diagnosed cancer patients in Germany per year? #WorldCanceResearchDay reminds us to never stop looking for a cure! At Tubulis we create advanced #ADCs to deliver better outcomes for patients. Find out how @ bit.ly/3R2Ntd9

Congratulations to this year’s #Nobelprize winners in #Chemistry, particularly Carolyn Bertozzi, whose bioorthogonal reactions are key for the improvement of targeted #cancer pharmaceuticals, including modern #ADCs. This is well deserved!

Interested in meeting the Tubulis Team at #BIOEurope 2022 in Leipzig to discuss the future of #ADCs? Reach out to us via BIO-Europe’s #partnering portal: bit.ly/3rlmVc6

Listen to our Head of Research Chemistry, Marc-André Kasper, talking about improvements in #ADC payload delivery targeting topoisomerase-I at the #FestivalOfBiologics on Nov 2 at 2:20pm CET. Find the agenda here bit.ly/3TwEr9J

We are excited to announce the appointment of Björn Hock, PhD, as Chief Development Officer! He has been advising us since 2020 & will support the rapid advancement of our #ADC candidates toward the clinic & expansion of our pipeline. Read the full PR here bit.ly/3YVxfXe

Attending the Next-Gen Conjugates Summit? Don’t miss the talk by our Director of Chemistry & Early Discovery, Marc-André Kasper, about our P5 & Alco5 platforms to create stable & efficient #ADCs & broaden the scope of drugs available for conjugation: bit.ly/3I5ujAr

We made it on the cover of the latest issue of the Royal Society of Chemistry’s flagship journal Chemical Science! Read our joint paper with The Hackenberger Group highlighting our novel P5-technology to create #ADCs with improved efficacy & PK here: rsc.li/3ZcOJyG. Cover by Barth van Rossum

Our CSO, Jonas Helma-Smets, & CDO, Björn Hock, are looking forward to the upcoming World ADC in #London! Interested to discuss our pipeline of highly stable & efficient #cancer #ADCs fueled by our novel #conjugation platforms? Reach out via [email protected] for a chat on-site

We are joining forces with Bristol Myers Squibb in a strategic #licensing agreement to develop differentiated next-generation antibody-drug conjugates (#ADCs) for the treatment of #cancer! Read the full PR here: bit.ly/3okIUSe

Attending the upcoming #BioEquity 2023? Meet our CEO, Dominik Schumacher on-site to discuss the latest #ADC developments and how our pipeline candidates aim to deliver the true potential of antibody-drug conjugates to #cancer patients.

Our CSO Jonas Helma-Smets will present a virtual poster on our novel #Alco5 platform highlighting its powerful potential to access a new spectrum of payloads for #ADC development PEGS Summit this week. Connect with him virtually to learn more! #solidtumors

Join the Tubulis team in Boston for #BIO2023. With the recent momentum in the #ADC space, we are looking forward to connecting with industry partners & the investor community to share the potential applications of our candidates for the future of #cancer treatment.

Don’t miss the workshop & 2 presentations by our colleagues Marc-André Kasper & Olivier Marcq, discussing linker selection & novel #conjugation technologies at the upcoming #ADC Linker & Conjugation Summit starting tomorrow in #Boston. 🛈 Agenda details bit.ly/3skdu0f